SNOA
Price:
$2.85
Market Cap:
$3.82M
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea ...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2007-01-25
Stock Exchange
NASDAQ
Ticker
SNOA
According to Sonoma Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.88. This represents a change of 250.62% compared to the average of -0.82 of the last 4 quarters.
The mean historical PE Ratio of Sonoma Pharmaceuticals, Inc. over the last ten years is -0.98. The current -2.88 PE Ratio has changed 29.37% with respect to the historical average. Over the past ten years (40 quarters), SNOA's PE Ratio was at its highest in in the September 2020 quarter at 35.01. The PE Ratio was at its lowest in in the September 2021 quarter at -32.70.
Average
-0.98
Median
-1.08
Minimum
-3.21
Maximum
3.27
Discovering the peaks and valleys of Sonoma Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 278.84%
Maximum Annual PE Ratio = 3.27
Minimum Annual Increase = -311.46%
Minimum Annual PE Ratio = -3.21
Year | PE Ratio | Change |
---|---|---|
2024 | -0.29 | -55.29% |
2023 | -0.64 | -69.24% |
2022 | -2.09 | -34.91% |
2021 | -3.21 | 30.81% |
2020 | -2.46 | 278.84% |
2019 | -0.65 | -44.23% |
2018 | -1.16 | -135.60% |
2017 | 3.27 | -311.46% |
2016 | -1.54 | 56.18% |
2015 | -0.99 | -114.23% |
The current PE Ratio of Sonoma Pharmaceuticals, Inc. (SNOA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.01
5-year avg
-1.74
10-year avg
-0.98
Sonoma Pharmaceuticals, Inc.’s PE Ratio is less than China Pharma Holdings, Inc. (-0.70), less than Universe Pharmaceuticals INC (-0.38), less than Acorda Therapeutics, Inc. (-0.00), less than Akanda Corp. (-0.04), less than Petros Pharmaceuticals, Inc. (-0.25), less than Sunshine Biopharma, Inc. (-0.71), less than Guardion Health Sciences, Inc. (0.65), greater than Alpha Teknova, Inc. (-10.30), less than Cannara Biotech Inc. (11.32), greater than MC Endeavors, Inc. (-17.36), less than Unrivaled Brands, Inc. (-1.51), greater than GelStat Corporation (-5.02), less than Shionogi & Co., Ltd. (1.97), greater than Alimera Sciences, Inc. (-20.50), less than China SXT Pharmaceuticals, Inc. (-0.06), less than Shuttle Pharmaceuticals Holdings, Inc. (-0.23), less than Lifecore Biomedical, Inc. (34.50), less than Mallinckrodt plc (-0.04), greater than Journey Medical Corporation (-6.01),
Company | PE Ratio | Market cap |
---|---|---|
-0.70 | $3.71M | |
-0.38 | $3.04M | |
-0.00 | $821.03K | |
-0.04 | $1.94M | |
-0.25 | $2.70M | |
-0.71 | $4.72M | |
0.65 | $4.35M | |
-10.30 | $390.75M | |
11.32 | $38.30M | |
-17.36 | $364.07K | |
-1.51 | $58.13K | |
-5.02 | $247.19K | |
1.97 | $11.45B | |
-20.50 | $301.29M | |
-0.06 | $1.33M | |
-0.23 | $3.19M | |
34.50 | $269.21M | |
-0.04 | $4.52M | |
-6.01 | $112.18M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sonoma Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Sonoma Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Sonoma Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Sonoma Pharmaceuticals, Inc. (SNOA)?
What is the highest PE Ratio for Sonoma Pharmaceuticals, Inc. (SNOA)?
What is the 3-year average PE Ratio for Sonoma Pharmaceuticals, Inc. (SNOA)?
What is the 5-year average PE Ratio for Sonoma Pharmaceuticals, Inc. (SNOA)?
How does the current PE Ratio for Sonoma Pharmaceuticals, Inc. (SNOA) compare to its historical average?